-
恶性肿瘤的发病率逐年攀升,其临床表现隐匿,早期诊断和治疗对改善患者预后及提高生存率至关重要。近20年来,PET/CT在肿瘤临床诊疗中的应用日益广泛,并获得了越来越多临床医师和患者的认可。18F-FDG是目前最常用的PET/CT正电子显像剂,其在鉴别病灶的良恶性、恶性肿瘤治疗的疗效评估以及疾病的术前评估中具有重要作用,是临床上不可或缺的影像学辅助手段。但颅脑和胃肠道等部位也会生理性摄取18F-FDG,这会在一定程度上降低PET/CT的诊断准确率。2019年,一种新型的正电子放射性示踪剂即68Ga标记的成纤维细胞激活蛋白抑制剂(fibroblast activation protein inhibitor,FAPI)问世,其可在近30种不同类型的恶性肿瘤中呈高摄取,且具有高T/NT的特性,未来或可替代传统的18F-FDG[1]。我们就68Ga-FAPI的靶点作用机制及临床应用作一综述。
68Ga-FAPI在疾病诊疗中的应用
Application of 68Ga-FAPI in disease diagnosis and treatment
-
摘要: 应用PET/CT诊断技术对恶性肿瘤患者进行早期诊断对其预后评估尤为重要,18F-氟脱氧葡萄糖(FDG)是目前核医学PET/CT诊断中最常用的正电子显像剂,其在鉴别病灶的良恶性、恶性肿瘤治疗的疗效评估以及疾病的术前评估中具有极大优势,已成为临床诊断不可或缺的影像学辅助手段。但其应用也有不便之处(如对患者有血糖和空腹的要求)。此外,颅脑和胃肠道的生理性摄取可能也会不同程度地影响临床医师做出正确诊断。68Ga标记的成纤维细胞激活蛋白抑制剂(FAPI)是一种以成纤维细胞激活蛋白为靶点的新型正电子显像剂,因其具有检查前患者无需禁食和静息等以及T/NT高等优势,已成为研究热点。笔者就68Ga-FAPI的靶点作用机制及临床应用进行综述。
-
关键词:
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 肿瘤 /
- 成纤维细胞激活蛋白 /
- 成纤维细胞激活蛋白抑制剂
Abstract: The application of PET/CT for early diagnosis of patients with malignant tumors is particularly important for their prognostic assessment. 18F-fluorodeoxyglucose (FDG) is currently the most commonly used positron imaging agent of PET/CT in nuclear medicine. It has great advantages in the differentiation of benign and malignant lesions, evaluation of the curative effect of malignant tumor treatment, and the preoperative evaluation of diseases, thus becoming an indispensable imaging aid for clinical diagnosis. But its application also has some inconveniences, such as the requirements of blood glucose and fasting for patients. In addition, the physiological uptake of brain and gastrointestinal tract may also affect clinicians to make correct diagnosis in varying degrees. By contrast, 68Ga-labeled fibroblast activation protein inhibitor (FAPI) is a new type of positron imaging agent targeting fibroblast activation protein. Its high T/NT and no additional requirements like fasting or bed rest for patients make it a hit in the research field. This paper reviews the target mechanism and clinical application of 68Ga-FAPI. -
[1] Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer[J]. J Nucl Med, 2019, 60(6): 801−805. DOI: 10.2967/jnumed.119.227967. [2] Giesel FL, Kratochwil C, Lindner T, et al. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers[J]. J Nucl Med, 2019, 60(3): 386−392. DOI: 10.2967/jnumed.118.215913. [3] Rettig WJ, Chesa PG, Beresford HR, et al. Differential expression of cell surface antigens and glial fibrillary acidic protein in human astrocytoma subsets[J]. Cancer Res, 1986, 46(12 Pt 1): 6406−6412. [4] Jacob M, Chang L, Puré E. Fibroblast activation protein in remodeling tissues[J]. Curr Mol Med, 2012, 12(10): 1220−1243. DOI: 10.2174/156652412803833607. [5] Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy[J]. Mol Cancer Ther, 2012, 11(2): 257−266. DOI: 10.1158/1535-7163.Mct-11-0340. [6] Shiga K, Hara M, Nagasaki T, et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth[J/OL]. Cancers, 2015, 7(4): 2443−2458[2020-06-10]. https://doi.org/10.3390/cancers7040902. DOI: 10.3390/cancers7040902. [7] Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy[J]. Proteomics Clin Appl, 2014, 8(5/6): 454−463. DOI: 10.1002/prca.201300095. [8] Chen WT, Kelly T. Seprase complexes in cellular invasiveness[J]. Cancer Metastasis Rev, 2003, 22(2/3): 259−269. DOI: 10.1023/a:1023055600919. [9] Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α[J]. FEBS J, 2011, 278(8): 1316−1332. DOI: 10.1111/j.1742-4658.2011.08051.x. [10] Loeffler M, Krüger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. J Clin Invest, 2006, 116(7): 1955−1962. DOI: 10.1172/jci26532. [11] Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α[J]. Science, 2010, 330(6005): 827−830. DOI: 10.1126/science.1195300. [12] Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice[J]. J Clin Invest, 2009, 119(12): 3613−3625. DOI: 10.1172/jci38988. [13] Egger C, Cannet C, Gérard C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis[J]. Eur J Pharmacol, 2017, 809: 64−72. DOI: 10.1016/j.ejphar.2017.05.022. [14] Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction[J]. J Mol Cell Cardiol, 2015, 87: 194−203. DOI: 10.1016/j.yjmcc.2015.08.016. [15] Puré E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics[J]. Oncogene, 2018, 37(32): 4343−4357. DOI: 10.1038/s41388-018-0275-3. [16] Chen HJ, Pang YZ, Wu JX, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 1820−1832. DOI: 10.1007/s00259-020-04769-z. [17] Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. J Nucl Med, 2018, 59(9): 1415−1422. DOI: 10.2967/jnumed.118.210443. [18] Giesel FL, Heussel CP, Lindner T, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis[J]. Eur J Nucl Med Mol Imaging, 2019, 46(8): 1754−1755. DOI: 10.1007/s00259-019-04346-z. [19] Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl Med, 2018, 59(9): 1423−1429. DOI: 10.2967/jnumed.118.210435. [20] Meyer C, Dahlbom M, Lindner T, et al. Radiation dosimetry and biodistribution of 68GA-FAPI-46 PET imaging in cancer patients[J]. J Nucl Med, 2020, 61(8): 1171−1177. DOI: 10.2967/jnumed.119.236786. [21] Chen HJ, Zhao L, Ruan D, et al. 68Ga-FAPI PET/CT improves therapeutic strategy by detecting a second primary malignancy in a patient with rectal cancer[J]. Clin Nucl Med, 2020, 45(6): 468−470. DOI: 10.1097/rlu.0000000000003000. [22] Lindner T, Altmann A, Krämer S, et al. Design and development of 99mTc labeled FAPI-tracers for SPECT-Imaging and 188Re therapy[J]. J Nucl Med, 2020, 61(10): 1507−1513. DOI: 10.2967/jnumed.119.239731. [23] Khreish F, Rosar F, Kratochwil C, et al. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease[J]. Eur J Nucl Med Mol Imaging, 2020, 47(8): 2040−2041. DOI: 10.1007/s00259-019-04623-x. [24] Koerber SA, Staudinger F, Kratochwil C, et al. The role of 68Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience[J]. J Nucl Med, 2020, 61(9): 1331−1336. DOI: 10.2967/jnumed.119.237016. [25] Voltin CA, Mettler J, Grosse J, et al. FDG-PET imaging for Hodgkin and diffuse large B-cell lymphoma— an updated overview[J/OL]. Cancers, 2020, 12(3): 601[2020-06-10]. https://www.mdpi.com/2072-6694/12/3/601. DOI: 10.3390/cancers12030601. [26] Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades typeⅠcollagen in thin-cap fibroatheromata[J]. Eur Heart J, 2011, 32(21): 2713−2722. DOI: 10.1093/eurheartj/ehq519. [27] Meletta R, Müller Herde A, Chiotellis A, et al. Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging[J/OL]. Molecules, 2015, 20(2): 2081−2099[2020-06-10]. https://www.mdpi.com/1420-3049/20/2/2081. DOI: 10.3390/molecules20022081. [28] Laverman P, van der Geest T, Terry SYA, et al. Immuno-PET and immuno-SPECT of rheumatoid arthritis with radiolabeled anti-fibroblast activation protein antibody correlates with severity of arthritis[J]. J Nucl Med, 2015, 56(5): 778−783. DOI: 10.2967/jnumed.114.152959. [29] van der Geest T, Laverman P, Gerrits D, et al. Liposomal treatment of experimental arthritis can be monitored noninvasively with a radiolabeled anti-fibroblast activation protein antibody[J]. J Nucl Med, 2017, 58(1): 151−155. DOI: 10.2967/jnumed.116.177931. [30] Varasteh Z, Mohanta S, Robu S, et al. Molecular imaging of fibroblast activity after myocardial infarction using a 68Ga-labeled fibroblast activation protein inhibitor, FAPI-04[J]. J Nucl Med, 2019, 60(12): 1743−1749. DOI: 10.2967/jnumed.119.226993. [31] Sonni I, Lee-Felker S, Memarzadeh S, et al. 68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation[J]. Eur J Nucl Med Mol Imaging, 2021, 48(3): 924−926. DOI: 10.1007/s00259-020-04947-z. [32] Hao B, Wu XR, Pang YZ, et al. [18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions[J]. Eur J Nucl Med Mol Imaging, 2021, 48(2): 651−652. DOI: 10.1007/s00259-020-04941-5. [33] Luo YP, Pan QQ, Zhang W. IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2019, 46(12): 2625−2626. DOI: 10.1007/s00259-019-04478-2. [34] Pan QQ, Luo YP, Zhang W. Recurrent immunoglobulin G4-related disease shown on 18F-FDG and 68Ga-FAPI PET/CT[J]. Clin Nucl Med, 2020, 45(4): 312−313. DOI: 10.1097/RLU.0000000000002919. [35] Luo YP, Pan QQ, Yang HX, et al. Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI for imaging IgG4-related disease: comparison to 18F-FDG PET/CT[J]. J Nucl Med, 2021, 62(2): 266−271. DOI: 10.2967/jnumed.120.244723. [36] Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases[J]. Am J Surg Pathol, 2010, 34(12): 1812−1819. DOI: 10.1097/PAS.0b013e3181f7266b. [37] Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase Ⅱtrial of sibrotuzumab in patients with metastatic colorectal cancer[J]. Onkologie, 2003, 26(1): 44−48. DOI: 10.1159/000069863. [38] 姚兰琳, 吴华, 郭崴. 乳腺癌核素靶向诊疗一体化的研究进展[J]. 国际放射医学核医学杂志, 2020, 44(11): 728−735. DOI: 10.3760/cma.j.cn121381-201909026-00081.
Yao LL, Wu H, Guo W. Research progress in integrated radionuclide targeted diagnosis and treatment of breast cancer[J]. Int J Radiat Med Nucl Med, 2020, 44(11): 728−735. DOI: 10.3760/cma.j.cn121381-201909026-00081.[39] Watabe T, Liu YW, Kaneda-Nakashima K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu- and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models[J]. J Nucl Med, 2020, 61(4): 563−569. DOI: 10.2967/jnumed.119.233122. [40] Lo A, Wang LCS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells[J]. Cancer Res, 2015, 75(14): 2800−2810. DOI: 10.1158/0008-5472.Can-14-3041. [41] Puré E, Lo A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors?[J]. Cancer Immunol Res, 2016, 4(4): 269−278. DOI: 10.1158/2326-6066.Cir-16-0011. [42] 黄超群, 耿霞飞, 刘九洋, 等. 间质成纤维细胞激活蛋白对胃癌细胞SGC7901生物学行为的作用[J]. 武汉大学学报: 医学版, 2020, 41(1): 39−43. DOI: 10.14188/j.1671-8852.2019.0042.
Huang CQ, Geng XF, Liu JY, et al. Effect of stromal fibroblast activation protein alpha on the biological behaviors of gastric cancer cell SGC7901[J]. Med J Wuhan Univ, 2020, 41(1): 39−43. DOI: 10.14188/j.1671-8852.2019.0042.[43] 唐婷婷. 成纤维细胞激活蛋白对卵巢癌细胞增殖和凋亡的影响[J]. 中国现代医生, 2019, 57(36): 34−36.
Tang TT. Effect of fibroblast activation protein on proliferation and apoptosis of ovarian cancer cell[J]. China Mod Doctor, 2019, 57(36): 34−36.
计量
- 文章访问数: 6233
- HTML全文浏览量: 5980
- PDF下载量: 76